Pharmaceutical and Medical Device
King & Spalding’s Pharmaceutical & Medical Device practice is consistently recognized as among the best in the nation. Our knowledge of the industry, combined with our broad capabilities and a deep bench of first-chair trial attorneys, allow us to handle any aspect of drug and device litigation, from early case assessment, through discovery, and on to trial and exit strategies.
January 6, 2025
FDA Issues Draft Guidance on Accelerated Approval Focused on How the Agency Will Implement New Authorities
December 13, 2024
FDA Publishes Final Predetermined Change Control Plan Guidance for AI-Enabled Device Software Functions
September 4, 2024
Transitional Coverage for Emerging Technologies: CMS’s Latest, But Not Necessarily Greatest, Coverage with Evidence Approach
November 19, 2024
King & Spalding Continues Antitrust Growth with Addition of Partner Olivier N. Antoine in New York
October 28, 2024
Antitrust Litigator Ross Elfand Joins King & Spalding in New York
October 28, 2024
Antitrust partner Ross Elfand joins the firm’s Business Litigation practice group in New York
January 7, 2025
King & Spalding Secures Defense Jury Verdict for Johnson & Johnson in Cosmetic Talcum Powder Litigation